Shares of Coherus (NASDAQ: CHRS) rallied as much as 21.7% early Monday, then gave up its gains to trade up around 2.4% as of 2:40 p.m. ET. This occurred after the company announced an agreement to ...

Investing.com -- Coherus BioSciences Inc (NASDAQ:CHRS) 股价在周五盘前交易中暴跌14.5%，此前该肿瘤公司宣布以每股1.75美元的价格公开发行2860万股股票。 发行价格较该股此前收盘价有显著折价，引发了股价的急剧下跌。Coherus预计将从此次发行中筹集约5010万美元的总收益，不包括承销折扣和佣金。

UDENYCA net product sales were $50.9 million in Q2 2024, an increase of 19% compared to $42.7 million in Q1 2024 and a 60% increase compared to $31.7 million in Q2 2023. Total unit demand increased 25 ...

A disappointing quarter combined with a set of analyst price target cuts -- and even a recommendation downgrade -- made Coherus BioSciences (NASDAQ: CHRS) a stock to avoid this week. As of ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) shares are trading higher Wednesday after the company announced the FDA approval of its pegfilgrastim delivery device, Udenyca Onbody. Coherus BioSciences ...

Analyst Douglas Tsao of H.C. Wainwright maintained a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price target of $11.00. Douglas Tsao’s rating is based on a comprehensive review ...

The immuno-oncology biotech specialist delivered stronger-than-expected revenue and earnings in Q2. Coherus also reiterated its full-year guidance and anticipates closing on its pending merger with ...

(Reuters) -Coherus BioSciences said on Monday it has launched a copycat version of AbbVie's Humira in the United States at a discount of more than 85% to the blockbuster arthritis drug. Coherus is the ...

Recall shares of Coherus fell under pressure back in September after the FDA issued a complete response letter (CRL) for its Udenyca OnBody biologics license application. Coherus was quick to point ...

(Reuters) -Coherus BioSciences Inc said on Thursday it plans to launch a biosimilar of AbbVie Inc's Humira in July at a list price of $995 per carton, representing a discount of about 85% from the ...

Coherus BioSciences said on June 22 it had agreed to retract a restraining order against AbbVie regarding the launching of a lower-priced version of rheumatoid arthritis drug Humira, according to a ...